-
UCL Cancer Institute-led study defines standard of care for non-Hodgkin lymphoma
from the CR-UK UCL Clinical Trials Centre.
Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensifi cation with 14-day versus 21-day cycles....
-
BioMarin Licenses Factor VIII Gene Therapy Program for Hemophilia A.
AN RAFAEL, Calif., Feb. 21, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced that it has licensed a Factor VIII gene therapy program for hemophilia A from UCL and St Jude Children's ....
-
Not Just a Walk in the Park for the UCL Cancer Institute.
Cure Cancer @ UCL Charity (Registered Charity No 1141310) would like to invite you to join us and Dima Yeremenko with the Good Boy Dog School to take your pet on a beautiful stroll around Kensington Gardens....
-
Scientists put the brakes on runaway brain tumours.
An international effort to improve our knowledge of the behaviour of one of the most aggressive and lethal forms of brain tumour has yielded exciting...
-
MSc Cancer, applications are now being accepted for the 2013-2014 academic year.
Please apply early to avoid disappointment. The closing date for applications is 2nd August 2013. There is a maximum of 35 students accepted onto the program per annum. .. -
Order from Chaos: Deciphering the basis for Genetic Diversity in Colon cancer.
Increasing evidence suggests that individual tumours are comprised of major genetic differences between cells of the same tumour resulting in chaotic genomes in individual cancers... -
Latest Issue Cancer Institute Newsletter is now available
During the past 5 years, one of the most transformative changes in cancer research has been the mundane use of high-through-put technologies to decipher millions, rather than tens or hundreds, of .. -
Dormant Cancer Cells explains Resistance to Therapy.
Childhood leukaemia remains a model disease to study the biology of cancer. Important questions in cancer research are how ancer cells survive for many years before giving rise to secondaries.. -
Collaboration Cellectis (genome engineering) with UCL Cancer Institute.
Cellectis (Paris, France), a genome engineering specialist company, announces the signing of a broad collaboration agreement with researchers at the UCL Cancer Institute..
stop
stop
stop
stop
stop
stop
stop
stop
stop